SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: Özel Sayı 1

Achievements of the COVID-19 Turkey Platform in vaccine and drug development with an approach of “co-creation and succeeding together”

Hasan MANDAL
Pages
3139–3149
Publication Date
2022-11-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review article discusses the advances that are achieved by the COVID-19 Turkey Platform from the ecosystem perspective, emphasizing the important scientific advances that have been achieved in the field of medical sciences.Key words: Vaccine, drug, COVID-19, SARS-CoV-2, co-creation

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract: Mobilizing the research ecosystem for accelerating vaccine and drug development has been an important reality of the pandemic.
📊
Key Findings & Data:This article reviews the scientific advances that are attained by the COVID-19 Turkey Platform for vaccine and drug development against the SARS-CoV-2 virus.
💡
Conclusion & Impact:This review article discusses the advances that are achieved by the COVID-19 Turkey Platform from the ecosystem perspective, emphasizing the important scientific advances that have been achieved in the field of medical sciences.Key words: Vaccine, drug, COVID-19, SARS-CoV-2, co-creation
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Abstract: Mobilizing the research ecosystem for accelerating vaccine and drug development has been an important reality of the pandemic. This article reviews the scientific advances that are attained by the COVID-19 Turkey Platform for vaccine and drug development against the SARS-CoV-2 virus. The platform that is coordinated by the Scientific and Technological Research Council of Turkey is established with a “co-creation and succeeding together” approach, which involves 436 researchers across 49 different institutions working on 17 vaccine and drug development projects in total. Recent advances of the COVID-19 Turkey Platform include the fourth virus-like particle-based vaccine candidate in the world to enter clinical studies based on the World Health Organization COVID-19 vaccine tracker that is currently completing phase 2 clinical studies on the path towards initiating phase 3 clinical studies. Moreover, an adjuvanted inactivated vaccine candidate and two drug candidates that have been identified through the virtual scanning of more than 20,000 molecules are currently in clinical studies. Other vaccines and drug candidates involve additional innovative aspects, and a locally synthesized drug is found to have an impact on COVID-19. This review article discusses the advances that are achieved by the COVID-19 Turkey Platform from the ecosystem perspective, emphasizing the important scientific advances that have been achieved in the field of medical sciences.Key words: Vaccine, drug, COVID-19, SARS-CoV-2, co-creation

🔖

Cite This Article

MANDAL, H. (2022). Achievements of the COVID-19 Turkey Platform in vaccine and drug development with an approach of “co-creation and succeeding together”. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: Özel Sayı 1, 3139–3149. https://ajindex.com/articles/609786

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. WHO (2020). WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available at:
  2. Ministry of Industry and Technology (2021). COVID-19 Turkey Platform. Available at: https://www.sanayi.gov.tr/ covid-19/asi-ilac-ve-tani-calismalari#kovid-19-turkiyeplatformu
  3. Mandal, H. (2020). Mobilizing the research ecosystem for scientific advances towards positive impact in the context of the COVID-19 Pandemic. Turkish J. Med. Sci. 50, 485–488. Available at: 10.3906/sag-2004-180
  4. Mandal, H. (2020). R&D and Innovation Approaches in the Postpandemic Period. In Reflections on the Pandemic in the Future of the World (Ankara: Turkish Academy of Sciences). Available at:
  5. TÜBİTAK (2020). COVID-19 Türkiye Platformu Aşı ve İlaç Geliştirme Sanal Konferansı Düzenledi. Available at: https:// covid19.tubitak.gov.tr/duyurular/covid-19-turkiye-platformuasi-ve-ilac-gelistirme-sanal-konferansi-duzenledi
  6. TÜBİTAK (2020). COVID-19 Türkiye Platformu Aşı ve İlaç Sanal Konferansı. Available at: https://covid19.tubitak.gov.tr/ arastirmalar/covid-19-turkiye-platformu-asi-ve-ilac-sanalkonferansi
  7. TÜBİTAK (2020). COVID-19 Data Portal Turkey. Available at:
  8. EC (2020). COVID-19 Data Portal. Available at: https://www. covid19dataportal.org/
  9. Forni, G., Mantovani, A., Forni, G., Mantovani, A., Moretta, L., Rappuoli, R., Rezza, G., Bagnasco, A., Barsacchi, G., Bussolati, G., et al. (2021). COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 28, 626–639. Available at:
  10. WHO (2021). COVID-19 Vaccine Tracker and Landscape. Available at:
  11. Kyriakidis, N.C., López-Cortés, A., González, E.V., Grimaldos, A.B., and Prado, E.O. (2021). SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines 6, 28. Available at:
  12. Klinman, D.M., Currie, D., Gursel, I., and Verthelyi, D. (2004). Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199, 201–216
  13. Klinman, D.M., Klaschik, S., Sato, T., and T